Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
- Sponsor
- University of Cologne
- Study ID
- NCT02626884
- Phase
- PHASE2
- Status
- Completed
Conditions
- Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ibrutinib — DRUG
Study Details
The purpose of this trial is to determine 1. Disease stabilization/response rate after six 21-day cycles of ibrutinib 2. Remission status after six, twelve and 20 21-day cycles of ibrutinib
Key Dates
- Start date
- Aug 31, 2016
- Status verified
- Apr 2021
- Primary completion
- Aug 31, 2020
- Completion
- Aug 31, 2020
Study Design
- Enrollment
- 14 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: IbrutinibAll patient receive ibrutinib at a dose of 560 mg/d for up to 20 21-day cycles
Primary Outcome Measure
Response Rate [ Time Frame: after 6 cycles (each cycle is 21 days) of Ibrutinib ]